Pipeline
Astrizi Bio is focused on developing treatments that address the underlying disease mechanism and deliver innovative therapies with superior efficacy and improved safety profile over marketed drugs.
Obesity
AS-005 is an oral small molecule that repairs mitochondrial damage and resolves inflammation. It has shown potent weight loss in a head-to-head study versus semaglutide, along with significant improvement in cardiometabolic parameters including glucose tolerance and lipid panel. AS-005 shows marked reduction in inflammatory markers and modulation of obesity-induced disorders.
Parkinson’s Disease
AS-006 is a brain penetrant, orally available modifier of mitochondrial metabolism. AS-006 has demonstrated strong neuroprotection, rescue of dopaminergic neurons and rescue of motor function across multiple (alpha-synucleinopathy, genetic and neurotoxin induced) models of Parkinson’s disease.
Neuropathic Pain
AS-002 is an oral small molecule, repairs mitochondria damage and resolves inflammation. It has demonstrated effective analgesia under broad inflammatory and neuropathic pain conditions without opioid-related or other adverse CNS effects
Alzheimer’s Disease
AS-XXX has demonstrated direct neuroprotective effects, restoration of neural networks and the reduction of inflammation in in vitro models of Alzheimer’s Disease.
Statistical Figures
10 years
Obesity reduces life expectancy by up to 10 years
170 Billion
Obesity induced diseases cost $170 billion annually by 2030
4 Trillion
Total economic cost of obesity is forecast at $4 trillion by 2035
200 Billion
Weight loss drugs are expected to sell $200 billion annually by 2030